How should Nextstellis (drospirenone/estradiol) be used in a perimenopausal woman, including dosing schedule, side effects, and contraindications?

Nextstellis Use in Perimenopause

Nextstellis (estetrol 14.2 mg/drospirenone 3 mg) is FDA-approved for contraception but is not indicated for perimenopausal hormone replacement therapy; perimenopausal women requiring both contraception and symptom management should use Nextstellis for pregnancy prevention while understanding it may provide secondary benefits for vasomotor symptoms, though traditional menopausal hormone therapy with transdermal estradiol plus micronized progesterone remains the evidence-based first-line treatment for menopausal symptoms. 1, 2, 3

FDA-Approved Indication and Limitations

• Nextstellis is indicated solely for contraception in females of reproductive potential, not for menopausal hormone therapy. 1
• The product may be less effective in women with BMI ≥30 kg/m², with decreasing efficacy as BMI increases. 1
• Nextstellis is contraindicated in women over 35 years who smoke due to increased cardiovascular risk. 1

Dosing Schedule for Contraception

• Standard regimen: One pink active tablet (estetrol 14.2 mg/drospirenone 3 mg) daily for 24 consecutive days, followed by one white inactive tablet daily for 4 days. 1
• Initiation: Start on the first day of menses (Day 1 start); if not starting on day 1, use backup non-hormonal contraception until 7 consecutive active tablets have been taken. 1
• Timing: Take at the same time each day, with or without food. 1
• Missed dose: If one pink tablet is missed, take it as soon as possible and continue the next tablet at the scheduled time, even if two tablets are taken in one day. 1

Contraindications (Absolute)

• High risk of arterial or venous thrombotic disease 1
• Current or history of breast cancer 1
• Hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or decompensated cirrhosis 1
• Renal impairment (due to drospirenone's antimineralocorticoid effects and hyperkalemia risk) 1
• Adrenal insufficiency 1
• Undiagnosed abnormal uterine bleeding 1
• Co-administration with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir 1
• Women over 35 years who smoke cigarettes 1

Key Side Effects and Monitoring

Common Adverse Reactions (≥2%)

• Bleeding irregularities, mood disturbance, headache, breast symptoms, dysmenorrhea, acne, weight increase, and decreased libido 1

Critical Safety Monitoring

• Hyperkalemia risk: Check serum potassium during the first treatment cycle in women on long-term medications that may increase potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin). 1
• Blood pressure: Monitor periodically; discontinue if blood pressure rises significantly. 1
• Thromboembolism: Do not start earlier than 4 weeks postpartum (>20 weeks gestation) due to increased thrombotic risk. 1
• Migraine: Discontinue if new, recurrent, persistent, or severe migraines develop. 1
• Liver function: Withhold or permanently discontinue for persistent or significant elevation of liver enzymes. 1

Perimenopausal Context: When to Use vs. Traditional HRT

Use Nextstellis When:

• The perimenopausal woman requires reliable contraception (perimenopause carries pregnancy risk until 12 months of amenorrhea). 4
• She is under 35 years or is a non-smoker over 35 years without other cardiovascular risk factors. 1
• She has no contraindications to combined hormonal contraceptives. 1

Switch to Traditional HRT When:

• The woman reaches confirmed menopause (12 months amenorrhea) and no longer needs contraception. 2, 5
• She develops contraindications to combined hormonal contraceptives (hypertension, thrombotic risk, smoking over age 35). 2, 1
• She requires targeted menopausal symptom management with evidence-based regimens (transdermal estradiol 50–100 µg/day plus micronized progesterone 200 mg for 12–14 days/month). 3, 6

Drospirenone-Specific Benefits in Perimenopause

• Antimineralocorticoid activity: Drospirenone blocks aldosterone receptors, promoting sodium/water excretion and potentially reducing blood pressure by 4–12 mmHg systolic and 4–9 mmHg diastolic in women with baseline hypertension. 7, 8, 9, 10
• Weight neutrality: Unlike other progestins, drospirenone may prevent fluid retention and weight gain associated with estrogen. 8, 9, 10
• Premenstrual symptom improvement: Reduces negative mood, water retention, and increased appetite in perimenopausal women with irregular cycles. 9

Estetrol-Specific Safety Profile

• Lower hepatic impact: Estetrol (E4) has negligible effects on liver protein synthesis, reducing drug-drug interactions and thrombotic risk compared to ethinyl estradiol. 11
• Neutral blood pressure effect: Pooled phase 3 trial data show estetrol 15 mg/drospirenone 3 mg is not associated with blood pressure changes after 13 cycles; hypertension incidence attributable to the drug was 0.2%. 12
• Tissue selectivity: E4 demonstrates minimal impact on breast tissue and vascular endothelium due to distinct receptor selectivity. 11

Practical Algorithm for Perimenopausal Women

Clinical Scenario	Recommended Action	Evidence
Age <35 years, needs contraception + symptom relief	Start Nextstellis; monitor BP and potassium at cycle 1	[1]
Age 35–50 years, non-smoker, needs contraception	Start Nextstellis if no cardiovascular risk factors; monitor BP quarterly	[1,4]
Age >35 years, smoker	Do not use Nextstellis; offer progestin-only pill (drospirenone 4 mg) or non-hormonal contraception	[1,13]
Hypertension (>140/90 mmHg)	Do not use Nextstellis; consider levonorgestrel IUD + low-dose transdermal estradiol if HRT needed	[2,1,4]
Confirmed menopause (12 months amenorrhea)	Transition to transdermal estradiol 50 µg/day + micronized progesterone 200 mg for 12–14 days/month	[3,6]
Renal impairment or adrenal insufficiency	Absolute contraindication to Nextstellis; use alternative contraception	[1]

Common Pitfalls to Avoid

• Do not prescribe Nextstellis to women over 35 who smoke—this is an absolute contraindication due to cardiovascular risk. 1
• Do not use Nextstellis as first-line menopausal hormone therapy—it is a contraceptive, not an FDA-approved HRT regimen. 1, 2
• Do not overlook hyperkalemia risk—always check potassium in the first cycle if the patient takes ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics. 1
• Do not continue Nextstellis if blood pressure rises significantly—switch to progestin-only or non-hormonal contraception. 1
• Do not assume Nextstellis provides the same endometrial protection as traditional HRT—the 24/4 regimen is designed for contraception, not for postmenopausal endometrial protection (which requires 12–14 days of progestin per month). 3, 1
• Do not start Nextstellis within 4 weeks postpartum—thrombotic risk is elevated. 1

Transition Strategy: Contraception to HRT

• When to transition: After 12 consecutive months of amenorrhea (confirmed menopause) or when contraception is no longer needed. 2, 5
• How to transition: Stop Nextstellis and initiate transdermal estradiol 50 µg/day patch (changed twice weekly) plus oral micronized progesterone 200 mg at bedtime for 12–14 consecutive days each 28-day cycle. 3, 6
• Why transdermal estradiol is preferred: Bypasses hepatic first-pass metabolism, reducing VTE risk, and does not raise triglycerides or blood pressure. 3, 6